Tail. ▇▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (A)(1) and (A)(2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such Tail Financing is provided to the Company by investors whom ▇▇▇▇▇▇▇▇▇▇ had contacted during the Term as set forth in Exhibit B attached hereto (as may be updated from time to time by the Company and ▇▇▇▇▇▇▇▇▇▇), or introduced, directly or indirectly, to the Company during Term; provided, however, that such Tail Financing is consummated during the period beginning on the date hereof and ending three months following the expiration of the Right of First Refusal period in Section (A)(4) above.
Appears in 2 contracts
Sources: Exclusive Agency Agreement (Kitov Pharma Ltd.), Exclusive Agency Agreement (Kitov Pharma Ltd.)
Tail. ▇▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (A)(1) and (A)(2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such Tail Financing is provided to the Company by investors whom ▇▇▇▇▇▇▇▇▇▇ had contacted and brought over-the-wall during the Term as set forth in Exhibit B attached hereto (as may be updated from time to time by the Company and ▇▇▇▇▇▇▇▇▇▇), or introduced, directly or indirectly, introduced to the Company during Term; provided, however, that such Tail Financing is consummated during the period beginning on the date hereof and ending three months following the expiration of the Right of First Refusal period in Section (A)(4) above.
Appears in 2 contracts
Sources: Exclusive Agency Agreement (Kitov Pharma Ltd.), Exclusive Agency Agreement (Kitov Pharma Ltd.)
Tail. ▇▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (A)(1) and (A)(2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such Tail Financing is provided to the Company by investors whom ▇▇▇▇▇▇▇▇▇▇ had contacted during the Term as set forth in Exhibit B attached hereto (as may be updated from time to time by the Company and ▇▇▇▇▇▇▇▇▇▇), or introduced, directly or indirectly, to the Company during Term; provided, however, that such Tail Financing is consummated during the period beginning on the date hereof and ending three months following the expiration of the Right of First Refusal period in Section (A)(4) above.
Appears in 1 contract
Sources: Exclusive Agency Agreement (Kitov Pharmaceuticals Holdings Ltd.)
Tail. ▇▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (A)(11) and (A)(22) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that any capital or funds in such Tail Financing is provided to the Company directly or indirectly by investors whom (i) in the case of a public Offering, ▇▇▇▇▇▇▇▇▇▇ had contacted directly during the Term as set forth in Exhibit B attached hereto (as may be updated from time or introduced to time by the Company and directly during the Term, or (ii) in the case of any other Offering, have been brought “over the wall” directly by ▇▇▇▇▇▇▇▇▇▇), or introduced, directly or indirectly, to the Company during Term; provided, however, that if such Tail Financing is consummated during at any time within the 12-month period beginning on the date hereof and ending three months following the expiration or termination of the Right of First Refusal period in Section (A)(4) abovethis Agreement.
Appears in 1 contract
Sources: Underwriting Agreement (Silexion Therapeutics Corp)
Tail. ▇▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (A)(11) and (A)(22) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such Tail Financing financing or capital is provided to received by the Company by from (i) in connection with a public Offering, investors whom ▇▇▇▇▇▇▇▇▇▇ had contacted during the Term as set forth in Exhibit B attached hereto (as may be updated from time or introduced to time by the Company and during the Term, or (ii) in connection with a non-Public Offering, investors whom ▇▇▇▇▇▇▇▇▇▇)▇ had brought over-the-wall during the Term, or introduced, directly or indirectly, to the Company during Term; provided, however, that if such Tail Financing is consummated during at any time within the 12-month period beginning on the date hereof and ending three months following the expiration or termination of this Agreement and a list of such investors is provided to the Right Company as promptly as practicable following the expiration or termination of First Refusal period in Section (A)(4) abovethis Agreement.
Appears in 1 contract
Sources: Exclusive Agency Agreement (Genetic Technologies LTD)
Tail. ▇W▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses (A)(1) and (A)(2) hereunder, calculated in the manner set forth therein, with respect to any public or private offering or other financing or capital-raising transaction of any kind (“Tail Financing”) to the extent that such Tail Financing is provided to the Company by investors whom ▇W▇▇▇▇▇▇▇▇▇ had contacted during the Term as set forth in Exhibit B attached hereto (as may be updated from time to time by the Company and ▇W▇▇▇▇▇▇▇▇▇), or introduced, directly or indirectly, to the Company during Term; provided, however, that such Tail Financing is consummated during the period beginning on the date hereof and ending three months following the expiration of the Right of First Refusal period in Section (A)(4) above.
Appears in 1 contract
Sources: Exclusive Agency Agreement (Kitov Pharmaceuticals Holdings Ltd.)
Tail. ▇▇▇▇▇▇▇▇▇▇ shall be entitled to compensation under clauses clause (A)(1) and (A)(21) hereunder, calculated in the manner set forth therein, with respect to any public or private equity offering or other financing or capital-raising transaction (and for the avoidance of doubt, excluding any kind strategic partnerships and/or debt financings) (“Tail Financing”) to the extent that such Tail Financing financing or capital is provided to the Company by investors whom ▇▇▇▇▇▇▇▇▇▇ had contacted during the Term as set forth in Exhibit B attached hereto (as may be updated from time introduced to time by the Company and (or whom the Company referred to ▇▇▇▇▇▇▇▇▇▇▇ in accordance with section B(ii) below), and such investors participated in a conference call or introduced, directly or indirectly, to a meeting in each case where the Company is actively participating during the Term; provided, however, that if such Tail Financing is consummated during at any time within the 3-month period beginning on the date hereof and ending three months following the expiration or termination of the Right of First Refusal period in Section (A)(4) abovethis Agreement.
Appears in 1 contract